MedTrace Logo

Study to Assess the Effect of Multiple Doses of Tradipitant on CYP3A4 Using Midazolam as a Substrate in Healthy Subjects

NCT02621385 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-04-27

No results posted yet for this study

Summary

This study is designed to evaluate the potential effect of administration of tradipitant on CYP3A4 using midazolam pharmacokinetics as markers.

The study will also further characterize the pharmacokinetics of tradipitant.

Conditions

  • Healthy Volunteers

Interventions

DRUG

tradipitant

test agent

DRUG

Midazolam

substrate for drug-drug interaction assessment

Sponsors & Collaborators

Principal Investigators

  • Milko Radicioni, MD · CROSS Research SA

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2016-02-29

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02621385 on ClinicalTrials.gov